Drug intelligence / Profile preview

APL-2401

Development stage: Preclinical
Lead developer: Asieris Pharmaceuticals
Modality: Small Molecules

Overview

APL-2401 is a small molecule drug developed by Asieris Pharmaceuticals. It acts as a dual antagonist of fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3). The compound is being investigated for the treatment of urologic neoplasms and is currently in preclinical development. Its mechanism involves inhibiting FGFR2 and FGFR3 signaling pathways, which are implicated in tumorigenesis and cancer progression[1][2].

Targets

FGFR3 (Fibroblast growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)

Beyond the preview

Go deeper on APL-2401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL-2401.

Explore the full profile